OTCMKTS:NPHC Nutra Pharma (NPHC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Nutra Pharma Stock (OTCMKTS:NPHC) Get Nutra Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume4,664 shsMarket Capitalization$720 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nutra Pharma Corporation is a development-stage medical technology company focusing on the research and development of therapeutic products for gastrointestinal disorders, notably those arising from opioid use. The company is advancing a portfolio of proprietary formulations designed to address opioid-induced constipation (OIC), a common side effect of pain management regimens. Its lead candidate, RIMSO-50, is an oral solution being evaluated for its potential to alleviate OIC by promoting bowel movements without compromising the effectiveness of opioid analgesics. Nutra Pharma is leveraging its in-house formulation capabilities and preclinical data to support ongoing regulatory submissions and potential partner collaborations. Nutra Pharma holds patent protection in key jurisdictions, including the United States, Europe and Israel, covering its novel formulations and methods of use. The company’s intellectual property strategy is aimed at securing market exclusivity and facilitating potential licensing agreements. Headquartered in Tel Aviv, Israel, Nutra Pharma is building its operational footprint with activities in North America and Europe. While the company remains in the clinical and regulatory phase, it seeks to advance its product pipeline through strategic partnerships and capital investment to bring its therapies to patients in need.AI Generated. May Contain Errors. Read More Receive NPHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NPHC Stock News HeadlinesHead to Head Contrast: Nutra Pharma (OTCMKTS:NPHC) and Rocket Pharmaceuticals (NASDAQ:RCKT)July 31 at 2:15 AM | americanbankingnews.comNutra Pharma Corp. (NPHC)July 2, 2026 | nasdaq.comYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire.August 2 at 1:00 AM | SmartAsset (Ad)Nutra Pharma Corp (NPHC)April 9, 2025 | uk.investing.comPharmaNutra SpA: Strong Sales Growth and International Expansion Reinforce Buy RatingSeptember 11, 2024 | markets.businessinsider.comBiscuit brand Britannia forays into healthtech with NutriPlus appApril 3, 2024 | msn.comNutra Pharma Corp. Reaches Settlement with SECMarch 22, 2024 | globenewswire.comCollegium PharmaceuticalMarch 3, 2024 | forbes.comSee More Headlines NPHC Stock Analysis - Frequently Asked Questions How were Nutra Pharma's earnings last quarter? Nutra Pharma Corp. (OTCMKTS:NPHC) announced its earnings results on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The company earned $0.03 million during the quarter. How do I buy shares of Nutra Pharma? Shares of NPHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nutra Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nutra Pharma investors own include Jumia Technologies (JMIA), Prospect Capital (PSEC), Tilray Brands (TLRY), AGNC Investment (AGNC) and Aktis Oncology (AKTS). Company Calendar Last Earnings8/17/2018Today8/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:NPHC CIK1119643 Webwww.nutrapharma.com Phone(954) 509-0911Fax877-895-5647Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.05 million Net Margins-364.90% Pretax Margin-364.90% Return on EquityN/A Return on Assets-159.08% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual Sales$380 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares7,159,740,000Free Float2,756,500,000Market Cap$720 thousand OptionableNot Optionable Beta0.85 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:NPHC) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredI’m betting on Peter Thiel’s next winner. Here’s why.SpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...The Oxford Club | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nutra Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nutra Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
